A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL
- Sponsors Cell Medica
- 12 Dec 2017 Results (n=11, data cut off:31 Jul 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 07 Apr 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
- 07 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.